(LMAT) LeMaitre Vascular - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5255582018

Allografts, Catheters, Biologic, Grafts, Valvulotomes

Stock: Health Care Equipment
Age 19.3y

MCap 2,002m
Avg Vol 151K (12.9M USD)

Beta 0.666
Volatility 34.86%

EPS (Earnings per Share)

EPS CAGR: -43.12%
EPS Trend: 43.1%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 12.31%
Rev. Trend: 96.6%

Last SUE: -1.10
Qual. Beats: 0

Dividends

Dividend Yield	0.94%
Yield on Cost 5y	1.85%
Yield CAGR 5y	16.12%
Payout Consistency	100.0%
Payout Ratio	36.5%

Risk via 5d forecast
Volatility	34.9%
Value at Risk 5%th	52.9%
Relative Tail Risk	-7.78%

Reward TTM
Sharpe Ratio	-0.37
Alpha	-23.79
CAGR/Max DD	0.71

Character TTM
Hurst Exponent	0.390
Beta	0.666
Beta Downside	0.706

Drawdowns 3y
Max DD	33.32%
Mean DD	11.69%
Median DD	10.81%

Description: LMAT LeMaitre Vascular January 14, 2026

LeMaitre Vascular Inc. (NASDAQ: LMAT) designs, manufactures, and sells a broad portfolio of vascular-surgery devices-including allograft tissue grafts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, biosynthetic grafts, and specialty closure systems-across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company reaches customers via a direct sales force and a network of distributors, and it also offers cryopreservation services for human cadaver tissue.

Key recent metrics: FY 2023 revenue reached approximately $210 million, up ~12% year-over-year, with an operating margin near 15% and R&D spending representing about 8% of sales. The vascular-device market is being propelled by an aging population, rising prevalence of peripheral artery disease, and a sustained shift toward minimally invasive, biologic-graft-based procedures, which together support a 5%-6% CAGR in U.S. healthcare spending on vascular therapies.

For a deeper, data-driven look at LMAT’s valuation and peer landscape, you might explore the analytical tools available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (53.3m TTM) > 0 and > 6% of Revenue (6% = 14.5m TTM)

FCFTA 0.11 (>2.0%) and ΔFCFTA 2.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 173.8% (prev 92.84%; Δ 81.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 73.3m > Net Income 53.3m (YES >=105%, WARN >=100%)

Net Debt (160.1m) to EBITDA (86.7m) ratio: 1.85 <= 3.0 (WARN <= 3.5)

Current Ratio 13.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (24.4m) change vs 12m ago 6.81% (target <= -2.0% for YES)

Gross Margin 70.97% (prev 68.34%; Δ 2.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.40% (prev 56.50%; Δ -7.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 18.69 (EBITDA TTM 86.7m / Interest Expense TTM 4.09m) >= 6 (WARN >= 3)

Altman Z'' 7.41

(A) 0.70 = (Total Current Assets 452.0m - Total Current Liabilities 33.3m) / Total Assets 598.1m

(B) 0.29 = Retained Earnings (Balance) 173.7m / Total Assets 598.1m

(D) 0.78 = Book Value of Equity 171.0m / Total Liabilities 219.1m

Total Rating: 7.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.37

1. Piotroski 6.0pt

2. FCF Yield 3.59%

3. FCF Margin 27.49%

4. Debt/Equity 0.49

5. Debt/Ebitda 1.85

6. ROIC - WACC (= 3.50)%

7. RoE 14.96%

8. Rev. Trend 96.57%

9. EPS Trend 43.06%

What is the price of LMAT shares?

As of January 21, 2026, the stock is trading at USD 85.80 with a total of 172,024 shares traded.
Over the past week, the price has changed by +2.95%, over one month by +1.53%, over three months by -2.29% and over the past year by -13.10%.

Is LMAT a buy, sell or hold?

LeMaitre Vascular has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold LMAT.

Strong Buy: 3
Buy: 2
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LMAT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	103.7	20.8%
Analysts Target Price	103.7	20.8%
ValueRay Target Price	97.6	13.8%

LMAT Fundamental Data Overview January 19, 2026

P/E Trailing = 38.0474
P/E Forward = 33.4448
P/S = 8.3137
P/B = 5.2847
P/EG = 1.9106
Revenue TTM = 240.9m USD
EBIT TTM = 76.4m USD
EBITDA TTM = 86.7m USD
Long Term Debt = 168.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.79m USD (from shortTermDebt, last quarter)
Debt = 185.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 160.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.85b USD (2.00b + Debt 185.6m - CCE 343.1m)
Interest Coverage Ratio = 18.69 (Ebit TTM 76.4m / Interest Expense TTM 4.09m)
EV/FCF = 27.86x (Enterprise Value 1.85b / FCF TTM 66.2m)
FCF Yield = 3.59% (FCF TTM 66.2m / Enterprise Value 1.85b)
FCF Margin = 27.49% (FCF TTM 66.2m / Revenue TTM 240.9m)
Net Margin = 22.14% (Net Income TTM 53.3m / Revenue TTM 240.9m)
Gross Margin = 70.97% ((Revenue TTM 240.9m - Cost of Revenue TTM 69.9m) / Revenue TTM)
Gross Margin QoQ = 75.28% (prev 70.02%)
Tobins Q-Ratio = 3.09 (Enterprise Value 1.85b / Total Assets 598.1m)
Interest Expense / Debt = 0.70% (Interest Expense 1.30m / Debt 185.6m)
Taxrate = 23.09% (5.21m / 22.6m)
NOPAT = 58.8m (EBIT 76.4m * (1 - 23.09%))
Current Ratio = 13.58 (Total Current Assets 452.0m / Total Current Liabilities 33.3m)
Debt / Equity = 0.49 (Debt 185.6m / totalStockholderEquity, last quarter 378.9m)
Debt / EBITDA = 1.85 (Net Debt 160.1m / EBITDA 86.7m)
Debt / FCF = 2.42 (Net Debt 160.1m / FCF TTM 66.2m)
Total Stockholder Equity = 356.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.94% (Net Income 53.3m / Total Assets 598.1m)
RoE = 14.96% (Net Income TTM 53.3m / Total Stockholder Equity 356.6m)
RoCE = 14.56% (EBIT 76.4m / Capital Employed (Equity 356.6m + L.T.Debt 168.4m))
RoIC = 11.21% (NOPAT 58.8m / Invested Capital 524.7m)
WACC = 7.71% (E(2.00b)/V(2.19b) * Re(8.37%) + D(185.6m)/V(2.19b) * Rd(0.70%) * (1-Tc(0.23)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.21%
[DCF Debug] Terminal Value 82.22% ; FCFF base≈53.1m ; Y1≈65.5m ; Y5≈111.6m
Fair Price DCF = 81.35 (EV 2.01b - Net Debt 160.1m = Equity 1.85b / Shares 22.7m; r=7.71% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 43.06 | EPS CAGR: -43.12% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.57 | Revenue CAGR: 12.31% | SUE: -1.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.62 | Chg30d=+0.031 | Revisions Net=+3 | Analysts=9
EPS next Year (2026-12-31): EPS=2.59 | Chg30d=+0.099 | Revisions Net=+4 | Growth EPS=+7.0% | Growth Revenue=+9.1%

Additional Sources for LMAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle